Its my understanding the specifics haven't been hammered out yet, but Gerald told me the subsidiary was formed for the purpose of positioning the company for financing deals. In the case of a JV, buyout, or partnership the financier may want to only invest in the MANF, or in the diagnostics. With this new set up that will be possible. He was very emphatic in stressing that shareholders will be compensated for revenues generated from the diagnostics subsidiary, so I would not worry about that.
Everyone should email him your questions... he's pretty good at getting back to investors in a timely manner if you don't annoy him. Gerald@amarantus.com. Or email the IR department if that doesn't work. L&A is the new one, their contact info is on the bottom of the latest PR.
News 
Market Data 
Discover 
